Effect of Levofloxacin on the viability of intracellular Chlamydia pneumoniae and modulation of proinflammatory cytokine production by human monocytes

被引:4
作者
Baltch, AL [1 ]
Smith, RP
Ritz, WJ
Carpenter, AN
Bopp, LH
Michelsen, PB
Carlyn, CJ
Hibbs, JR
机构
[1] Stratton Vet Affairs Med Ctr, Albany, NY USA
[2] Albany Med Coll, Albany, NY 12208 USA
[3] New York State Dept Hlth, Wadsworth Ctr Labs & Res, Albany, NY 12201 USA
关键词
D O I
10.1016/j.diagmicrobio.2004.07.009
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Although antibiotics are known to affect the intracellular growth of Chlamydia pneumoniae in acute infections, their efficacy in therapy for chronic infections, including atherosclerosis, remains debatable. Human monocyte-derived macrophages (MDM) obtained from monocytes of healthy donors were infected with C. pneumoniae AR-39 and treated with levofloxacin (8 mug/mL) immediately after infection (0 hours) or 24 hours after infection. Levofloxacin treatment at 24 hours, but not at 0 hours, resulted in a significant decrease in the number of C. pneumoniae inclusions within the MDM (p < 0.05). Also decreased were concentrations of proinflammatory cytokines tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta, IL-6, and IL-8 in the extracellular medium (p < 0.01). Viable counts in titrations remained similar to those in untreated controls. In summary, levofloxacin administered to MDM at serum-attainable levels 24 hours after C. pneumoniae infection significantly decreased inclusion counts and proinflammatory cytokine production, but did not eliminate the C. pneumoniae infection. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:205 / 212
页数:8
相关论文
共 36 条
  • [1] Chlamydia pneumoniae infection in human monocytes
    Airenne, S
    Surcel, HM
    Alakärppä, H
    Laitinen, K
    Paavonen, J
    Saikku, P
    Laurila, A
    [J]. INFECTION AND IMMUNITY, 1999, 67 (03) : 1445 - 1449
  • [2] Reliability of nested PCR for detection of Chlamydia pneumoniae DNA in atheromas:: Results from a multicenter study applying standardized protocols
    Apfalter, P
    Assadian, O
    Blasi, F
    Boman, J
    Gaydos, CA
    Kundi, M
    Makristathis, A
    Nehr, M
    Rotter, ML
    Hirschl, AM
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (12) : 4428 - 4434
  • [3] Levofloxacin kills Chlamydia pneumoniae and modulates interleukin 6 production by HEp-2 cells
    Baltch, AL
    Smith, RP
    Ritz, WJ
    Carpenter-Knaggs, A
    Michelsen, PB
    Carlyn, CJ
    Bopp, LH
    Hibbs, JR
    [J]. CHEMOTHERAPY, 2003, 49 (1-2) : 27 - 32
  • [4] Detection of Chlamydia pneumoniae DNA and antigen in the circulating mononuclear cell fractions of humans and koalas
    Bodetti, TJ
    Timms, P
    [J]. INFECTION AND IMMUNITY, 2000, 68 (05) : 2744 - 2747
  • [5] Chlamydia pneumoniae and atherosclerosis:: Critical assessment of diagnostic methods and relevance to treatment studies
    Boman, J
    Hammerschlag, MR
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 2002, 15 (01) : 1 - +
  • [6] Distribution of Chlamydia pneumoniae DNA in atherosclerotic carotid arteries:: Significance for sampling procedures
    Cochrane, M
    Pospischil, A
    Walker, P
    Gibbs, H
    Timms, P
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (04) : 1454 - 1457
  • [7] Standardizing Chlamydia pneumoniae assays:: Recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada)
    Dowell, SF
    Peeling, RW
    Boman, J
    Carlone, GM
    Fields, BS
    Guarner, J
    Hammerschlag, MR
    Jackson, LA
    Kuo, CC
    Maass, M
    Messmer, TO
    Talkington, DF
    Tondella, ML
    Zaki, SR
    Bandea, C
    Black, C
    O'Conner, S
    Papp, J
    Perilla, MJ
    Schuchat, A
    Stevens, V
    Van Beneden, CA
    Zell, ER
    Cohen, C
    Campbell, LA
    Wwang, SP
    Grayston, JT
    Deal, CD
    Gaydos, C
    Schindler, L
    Taylor, CE
    Mahony, J
    Fong, IW
    Leinonen, M
    Saikku, P
    Maas, M
    Ossewaarde, JM
    Persson, K
    Boman, J
    Apfalter, P
    [J]. CLINICAL INFECTIOUS DISEASES, 2001, 33 (04) : 492 - 502
  • [8] Chlamydial heat-shock protein-60 antibody and correlation with Chlamydia pneumoniae in atherosclerotic plaques
    Fong, IW
    Chiu, B
    Viira, E
    Tucker, W
    Wood, H
    Peeling, RW
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (10) : 1469 - 1473
  • [9] Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells
    Gaydos, CA
    Summersgill, JT
    Sahney, NN
    Ramirez, JA
    Quinn, TC
    [J]. INFECTION AND IMMUNITY, 1996, 64 (05) : 1614 - 1620
  • [10] Antibiotics for secondary prevention of coronary artery disease: An ACES hypothesis but we need to PROVE IT
    Gelfand, EV
    Cannon, CP
    [J]. AMERICAN HEART JOURNAL, 2004, 147 (02) : 202 - 209